| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 2578942 | Thérapie | 2013 | 7 Pages | 
Abstract
												This temporary and exceptional mechanism will authorize a recognized off-label prescription, which may be reimbursed and monitored for 3 years. These TURs will only concern a small portion of “off-label” drugs having yet a positive risk/benefit ratio (conditional MA) but this is far from matching with majority of off-label prescriptions. As such, and in order to improve the use of drugs, it is important to propose a control system for all “off-label” prescriptions with a dedicated committee: the “off-label” committee which would determine the frame of the “off-label” prescriptions.
											Keywords
												
											Related Topics
												
													Health Sciences
													Pharmacology, Toxicology and Pharmaceutical Science
													Pharmacology, Toxicology and Pharmaceutics (General)
												
											Authors
												Claire Le Jeunne, Nathalie Billon, Anne Dandon, participants of round table N° 3 of Giens XXVIII: participants of round table N° 3 of Giens XXVIII:, Driss Berdaï, Yolande Adgibi, Jean-François Bergmann, Régis Bordet, Anne Carpentier, 
											